| Molecular Formula | C18H13BrN2O4S2 |
| Molar Mass | 465.34 |
| Density | 1.74±0.1 g/cm3(Predicted) |
| Boling Point | 655.3±65.0 °C(Predicted) |
| Solubility | DMSO: 6.4 mg/mL (Need ultrasonic) |
| pKa | 2.97±0.10(Predicted) |
| Storage Condition | -20℃ |
| In vitro study | Treatment of MCF-7 cells with Skp2 inhibitor C1 reduced the proportion of cells in the G1 phase and increased the number of cells in the G2/M phase. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.149 ml | 10.745 ml | 21.49 ml |
| 5 mM | 0.43 ml | 2.149 ml | 4.298 ml |
| 10 mM | 0.215 ml | 1.074 ml | 2.149 ml |
| 5 mM | 0.043 ml | 0.215 ml | 0.43 ml |
| biological activity | Skp2 inhibitor C1 (SKPin C1) is a highly selective small molecule inhibitor of Skp2-mediated p27 degradation. |
| target | TargetValue p27 degradation () |
| Target | Value |
| in vitro study | treating MCF-7 cells with Skp2 inhibitor C1 can reduce the proportion of G1 phase cells and increase the number of G2/M phase cells. |